New Drugs for HDL-C Disorders: The Beginning

Author(s): MyNgan Duong, Stephen J. Nicholls

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 25 , 2014

Become EABM
Become Reviewer


For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.

Keywords: Atherosclerosis, cardiovascular disease, HDL, lipids, risk factors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [2947 - 2951]
Pages: 5
DOI: 10.2174/0929867321666140414104130
Price: $65

Article Metrics

PDF: 19